Works matching IS 15233790 AND DT 2013 AND VI 15 AND IP 3

Results: 15

Secondary Cytoreduction Versus Chemotherapy Alone in the Treatment of Patients with Recurrent Ovarian Cancer: Is a Randomized Trial Worthwhile?

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 191, doi. 10.1007/s11912-013-0302-z

By:

Sammartino, Paolo;
Biacchi, Daniele;
Framarino, Marialuisa

Publication type:

Article

New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 239, doi. 10.1007/s11912-013-0305-9

By:

Ezzell, Erin;
Chang, Kuang;
George, Benjamin

Publication type:

Article

Provider Impact on Survival Outcomes in the Management of Malignant Disease.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 193, doi. 10.1007/s11912-013-0304-x

By:

Markman, Maurie

Publication type:

Article

Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 232, doi. 10.1007/s11912-013-0309-5

By:

Nieto, Yago

Publication type:

Article

Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 276, doi. 10.1007/s11912-013-0312-x

By:

Trammel, Morgan;
Roederer, Mary;
Patel, Jai;
McLeod, Howard

Publication type:

Article

Novel Immunotherapies in GU Malignancies.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 224, doi. 10.1007/s11912-013-0306-8

By:

Drakaki, Alexandra;
McDermott, David

Publication type:

Article

Benefit and Harms of New Anti-Cancer Drugs.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 270, doi. 10.1007/s11912-013-0303-y

By:

Vera-Badillo, Francisco;
Al-Mubarak, Mustafa;
Templeton, Arnoud;
Amir, Eitan

Publication type:

Article

Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 197, doi. 10.1007/s11912-013-0313-9

By:

Fujiwara, Keiichi;
Kurosaki, Akira;
Hasegawa, Kosei

Publication type:

Article

Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 217, doi. 10.1007/s11912-013-0311-y

By:

Abouharb, Sausan;
Corn, Paul

Publication type:

Article

Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 249, doi. 10.1007/s11912-013-0308-6

By:

Belum, Viswanath;
Fischer, Alyssa;
Choi, Jennifer;
Lacouture, Mario

Publication type:

Article

The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 207, doi. 10.1007/s11912-013-0315-7

By:

Bradshaw, Michael;
Mansfield, Aaron;
Peikert, Tobias

Publication type:

Article

In Reply: Response to Sammartino et al.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 192, doi. 10.1007/s11912-013-0301-0

By:

Harter, Philipp;
Heitz, Florian;
Bois, Andreas

Publication type:

Article

Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 201, doi. 10.1007/s11912-013-0314-8

By:

Banerjee, Susana;
Gore, Martin

Publication type:

Article

Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 204, doi. 10.1007/s11912-013-0310-z

By:

Hoskins, Paul

Publication type:

Article

Clearing the Air: A Review of Our Current Understanding of 'Chemo Fog'.

Published in:

Current Oncology Reports, 2013, v. 15, n. 3, p. 260, doi. 10.1007/s11912-013-0307-7

By:

O'Farrell, Erin;
MacKenzie, Joyce;
Collins, Barbara

Publication type:

Article